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Odontogenic myxoma (OM) is a benign odontogenic neoplasm that tends to recur due to bone inﬁltra-
tion. This review focuses on the molecular aspects of the OM. The following topics are discussed: clonal
nature, matrix metalloproteinases, apoptosis and cell proliferation, genetic alterations, and other mark-
ers. Translational studies are necessary to identify the prognostic markers of this lesion, and also, molec-
ular biology studies may help to identify the etiologic factors and to develop more effective and less
aggressive approaches, other than surgery, to the treatment of this inﬁltrating odontogenic tumor.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction An abundant myxoid extracellular matrix (ECM) has been rec-Odontogenic myxoma (OM) is an intraosseous neoplasm that
comprises 3–20% of all odontogenic tumors and is characterized
by stellate and spindle-shaped cells embedded in an abundant
myxoid or mucoid extracellular matrix.1 It presents most com-
monly during the second or third decade of life. This tumor may
lead to an extensive bone expansion and usually inﬁltrates the
adjacent bone.2–5
The histogenesis of OM is most likely related to the odontogenic
ectomesenchyme of a developing tooth or undifferentiated mesen-
chymal cells in the periodontal ligament and there are many theo-
ries that support the odontogenic origin of the OM.6 These theories
are supported by the histological similarity between OM and pul-
pal ectomesenchyme, proximity to the tooth-bearing areas of the
jaws, periodic association with missing or unerupted teeth, occa-
sional presence of inactive odontogenic epithelium, and its uncom-
mon occurrence in other parts of the skeleton.6 Sivakumar et al.7
investigated a panel of antibodies to characterize and distinguish
the nature of the cells in odontogenic myxoma and suggested that
OM is a tumor of a dual ﬁbroblastic-histiocytic origin and the cells
comprising odontogenic myxoma are of myoﬁbroblastic origin.7Oral Surgery and Pathology,
rais, Av. Antônio Carlos, 6627,
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er OA license.ognized in various reactive and neoplastic lesions, including OM.8
The ECM is composed of glycosaminoglycans, proteoglycans, colla-
gens, ﬁbronectin, and tenascin.4,9,10 The speciﬁc composition and
the relative amount of each component contribute to the edema-
tous appearance of the myxoid ECM, facilitating diffusion of
metabolites and the formation of networks permissive for cell
growth and migration.8,11 Further studies comparing reactive le-
sions with benign and malignant neoplasms will help to elucidate
which speciﬁc component of ECM in OM is associated with its
invasive behavior.
There is no consensus regarding the mechanisms of invasive-
ness of OM and the theories include from expression of matrix
metalloproteinases (MMPs) to the expression of antiapoptotic pro-
teins, alterations in receptor activator of nuclear factor kappa B li-
gand (RANKL), its receptor RANK, and osteoprotegerin (OPG)
system, and genetic alterations.4,9,10
In this paper, we discuss the main molecular aspects of the OM,
highlighting the genetic alterations described so far, as well as the
published data about apoptosis and cell proliferation, MMPs, and
other markers that may take part in its pathogenesis.Clonal nature
An issue of controversy is the clonal/polyclonal origin of neopla-
sias. We recently published some results of odontogenic tumors
clonality assessment based on the HUMARA assay.12 We were only
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revealed monotypy at the HUMARA, the other was polyclonal.
Depending on the size of the patch, this monotypy may represent
a true monoclonality. Taking together the fact that the origin of the
OM is not clearly deﬁned and the size of the odontogenic patch is
not determined and one sample was polyclonal, the clonal nature
of such a lesion remains to be established.
MMPs
MMPs are a group of enzymes involved in regulating and
remodeling the ECM and play an important role in the regulation
of cell communication and other processes such as cell surface
receptors, cytokines, adhesion molecules, and growth factors.13,14
MMPs hydrolyze components of ECM and are synthesized by cells
of the connective tissue such as ﬁbroblasts, osteoblasts, and also by
odontoblasts.11 MMP-2 and -9 degrade type IV collagen, the major
component of the basal membrane, and due to this fact are associ-
ated with the invasive phenotype of some lesions.15 In addition, as
MMPs seem important in odontogenesis and considering that in
theory OM are derived from the tooth-forming ectomesenchyme9,
MMPs have been extensively investigated in these lesions.
Randall andHall16 reported the expressionofMMP-1, -2, -3, and -
9 during tooth development. They observed, during the bud stage,
that the MMPs were expressed within both epithelial and mesen-
chymal cells. During the cap stage, differential expression was ob-
served highlighting the expression of MMP-3 within the enamel
knot.MMP-9 immunoreactivitywas observed in both, the inner epi-
theliumof the enamel organ andpre-odontoblasts, withweak stain-
ing in dental papilla, suggesting a role of MMP-9 in odontogenesis,
acting especially on the degradation of the basement membrane
at the dental papilla/enamel organ interface.16 During the early bell
stage, the four MMPs were expressed in the inner enamel epithe-
lium, basement membrane, and pre-odontoblasts, but the dental
papilla presented a weak immunoexpression. In the late bell stage,
the expression of MMPs was negligible in the inner enamel epithe-
lium, the pre-ameloblasts were weakly positive, and, in the dental
papilla, the pre-odontoblasts were positive for the MMPs studied.16
Some years later, the role of MMPs in tooth development was eval-
uated using a culture of embryonic mouse tooth germs.17 The study
suggested thatMMP-2plays a role in basementmembranedegrada-
tion; thus, allowing physical communication between odontoblasts
and ameloblasts. At a later stage of development, its expression in
dental tissues was restricted to differentiated odontoblasts. MMP-
9, on the other hand, was intensely and transiently expressed in
the early dental mesenchyme surrounding the invaginating tooth
bud, but its expression diminished at the later stages.17
Using immunohistochemistry, Bast et al.18 showed that 90% of
OM cells (n = 26) stained positively for MMP-2 compared with pos-
itivity of 10% in myxomatous dental follicular tissue and myxoid
dental pulp used as controls. In this same publication, specimen
and control tissues were negative for MMP-3 and -9.18 Moreover,
attempting to improve the understanding of the OM local invasive-
ness capacity, Miyagi et al.11 investigated MMP-2 and -9 in tumor
samples as well as in cell line derived from OM. Contrasting to the
results of Bast et al.18, the authors demonstrated MMP-2 and -9
expression in all cells of an OM cell culture, using immunoﬂuores-
cence.11 However, this data should be analyzed with caution, once
it is based on a cell line originating from an OM and the experi-
ments were conducted between the 8th and 10th passages. As
the tumor cells interact with their ‘environment’, it is possible that
some original characteristics are lost or changed once these cells
are cultured and they no longer have contact with the ‘environ-
ment’. They also analyzed the expression and activity of MMP-2
and -9 in OM with zymographic analysis and demonstrated that
the active and latent MMP-9 were present in the tumoral cells,but the MMP-2 was only found latent in these cells, suggesting that
MMP-9 is important to the invasive behavior of OM.11
Analysis of the immunohistochemical expression of MMP-1 in
OM revealed a lower expression (66.7%) compared with that ob-
served in the ECM of dental papillae (75%) but this difference
was not signiﬁcant (p > 0.05), suggesting a possible role of this en-
zyme in the pathogenesis of OM.19 In parallel to the functions pro-
posed for this protease in degenerative processes and malignant
tumors,20,21 in OM the MMP-1 may act by remodeling the extracel-
lular matrix and by facilitating the dissemination of the tumor
through neighboring bone.19 This suggestion is supported by the
observation of an association between this MMP and adhesion
molecule receptors, such as integrins, as reported previously.13
The role of MMP in the invasion process of OM is still a matter
of debate. It was demonstrated that the OM expressed more MMP-
1 than MMP-2 and more MMP-2 than MMP-9,19 however, these
authors did not prove a different expression pattern of these MMPs
in OM when compared to tooth germs. As previously described by
Randall and Hall16, the MMPs-1, -2, -3, and -9 are expressed during
normal tooth development, exhibiting an important role in remod-
eling of ECM and in regulation of the shape of tooth germ. As the
majority of MMPs described in tooth development in different
stages are also described as positive in OM, it was not possible, un-
til now, to associate their temporospatial expression to the devel-
opment of OM. In addition, most of the present data is only based
on immunohistochemical results, which may lead to different re-
sults depending on factors such as sample ﬁxation, processing,
and different antibodies clones. Functional studies using cell cul-
ture are necessary for the better understanding of the role of MMPs
in OM growth. MMPs modulation can be an interesting target in fu-
ture OM molecular therapy.Apoptosis and cell proliferation
Bast et al.18 demonstrated an increased immunoexpression of
Bcl-2 and Bcl-x, antiapoptotic proteins, in OM (n = 26) compared
to the dental follicle and dental pulp. While an average of 6.5%
and 10.4% of tumor cells were positive for Bcl-2 and Bcl-x, respec-
tively, a positivity of about 1% in normal dental pulp tissues was
found for both proteins.18 In addition, Bak and Bax, proapoptotic
proteins, were not detected in tumor cells. As they found a low pro-
liferation activity in the same tumor samples, they pointed to the
production of antiapoptotic proteins as a possible mechanism of
tumor progression.18
However, a study of a large series of cases (n = 62) found less
than 1% of Bcl-2 and MIB-1 (Ki-67) positive cells in OM.22 Negative
staining for Bcl-2 was reported in another study including 12 sam-
ples,23 but MIB-1 (Ki-67) stained about 4% of the ‘stromal’ cells,
leading the authors to conclude that ‘OM mainly grows due to the
proliferative activity of the stromal cells’. As the 2 largest series of
studies with OM including 62 and 26 samples, respectively,18,22
demonstrated an overall low proliferation activity in the neoplasia,
it seems that the proliferative activity of tumor cells is not themajor
factor responsible for tumor growth. The apoptotic/antiapoptotic
proteins were investigated only based on immunohistochemistry
experiments, and the overall ﬁndings do not entirely support the
idea that the overexpression of antiapoptotic proteins is one of
the growth mechanisms of OM. New studies relying on more accu-
rate/sensitive techniques are needed to elucidate the real role of the
apoptotic/antiapoptotic proteins on the OM pathogenesis.Genetic alterations
Mutations that inhibit the GTPase activity of a subunit of the
stimulating G protein (Gsa) have been demonstrated in the
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et al.24 investigated the presence of Gs alpha gene mutations in
23 OMs and, although there are histopathological similarities
shared by cardiac and jaw myxomas, no Gs alpha mutations could
be demonstrated in any of the tumors analyzed by these authors.
Cyclic adenosine monophosphate (cAMP)-dependent protein
kinase A (PKA, EC 2.7.1.37) is the major mediator of the cAMP
effects in eukaryotic cells. In its inactive state, the PKA holoenzyme
is a tetramer comprised of a dimer of two regulatory subunits
bound to two catalytic subunits. When cellular cAMP concentra-
tions are elevated, two molecules of cAMP bind each of the regula-
tory subunits, which leads to dissociation of the tetramer into
regulatory dimers and two free catalytic subunits. The free
catalytic subunits represent active serine threonine kinases that
regulate downstream effector enzymes, ion channels, and tran-
scription of speciﬁc genes that mediate cell growth, proliferation,
and differentiation.25 In human, four different regulatory (RIa,
RIb, RIIa, and RIIb) and four catalytic subunits (Ca, Cb, Cg, and
PRKX) have been identiﬁed thus far.25
PRKAR1A is the gene encoding RI-a. This protein is a relatively
abundant regulatory subunit type 1A of cAMP-dependent PKA,
the central hub of all cAMP-related signaling. PRKAR1A-inactivating
mutation was identiﬁed as the founding mutation of the syndrome
known as Carney complex.26,27 This is a multiple endocrine neopla-
sia syndrome associated with various types of myxomas such as
cardiac and skin myxomas. OM is not related with Carney syn-
drome; however, cardiac myxoma and those of the skin and other
locations are not substantially different histologically from OM.
The same spindle-shaped cells appear in an abundant stroma of
myxoid material.28 Our research group in collaboration with other
group screened 17 odontogenic myxomas from patients without
Carney complex for PRKAR1A mutations and PRKAR1A protein
expression by immunohistochemistry.29 We found 53% of the
samples with decreased immunostaining for RI-a protein product
and 2 samples harboring previously undescribed mutations of the
PRKAR1A gene. One mutation (c.725C > A) led to a nonconservative
amino acid substitution in a highly conserved area of the gene; the
other was a single base-pair deletion that led to a frameshift
(del774C) and a stop codon, 11 amino acids downstream of the
mutation site; both tumors were heterozygous for the respective
mutations. Why a decrease in RI-a immunostaining in the remain-
ing tumors in the absence of any coding sequence PRKAR1A muta-
tions still needs to be explained. Tumor development-related
gene silencing through methylation or a related mechanism may
be the underlying explanation.29
PKA signaling is essential in embryonic meso- and ectodermal
differentiation. RI-a has ubiquitous distribution and is primarily
involved in the control of proliferation and neoplastic transforma-
tion. It also plays an important role in the transition from the G1 to
S phase of the cell cycle.30,31 RI-a-deﬁcient mice display a severe
phenotype, with gross developmental defects in mesodermal
morphogenesis and early embryonic lethality due to incomplete
development of the primitive heart tube.32 However, there are
conﬂicting data in the literature about PRKAR1A’s role in human
neoplasia, cancer cell lines, and animal models. In contrast with
the Carney complex that arises from loss of PRKAR1A, the expres-
sion of RI-a is frequently increased in several cancers. Functional
studies are necessary to delineate the role of PRKAR1A gene in
OM development and/or growth.
HMGA2, a member of a group of proteins related to tumor for-
mation through transcriptional activation of speciﬁc genes, was
studied by Sato et al.33 HMGA2 is a member of the high-mobility
group A proteins and was formerly referred to as HMGI-C. These
proteins are small non-histone, chromatin-associated proteins that
function as activators or repressors of gene expression through
transcription factors, being involved in ﬁbroadenomas of the breast,salivary gland and endometrial hyperplasia, pituitary adenomas,
enhanced adipogenesis, and others.33,34 HMGA2 may suppress the
cell cycle arrest at G1 that is mediated by p16Ink4a and p19Arf1,
and also senescence.35 The HMGA2 protein is widely expressed
during embryogenesis, but it is undetectable in most normal adult
human tissues. The overexpression of the protein is a constant fea-
ture of malignant tumors, whereas rearrangements of the HMGA2
gene are features of benign mesenchymal tumors. Sato et al.33 sug-
gested that HMGA2 rearrangement and HMGA2 protein overex-
pression might be associated with the tumorigenesis of OM.
Other markers
Osteoclast formation, differentiation, and activity are regulated
by RANK/RANKL/OPG system. Ligation of RANKL to RANK results in
the fusion, differentiation, and activation of osteoclasts, while OPG
inhibits this interaction.36 The majority of the mesenchymal cells
in OM exhibit a tendency to demonstrate a higher content of
RANKL than OPG.36 Translational studies are necessary to demon-
strate if RANKL/OPG index has impact on OM recurrence or
behavior.
Nestin is one of the intermediate ﬁlaments constituting the
cytoskeleton, a marker of neural stem cells or progenitor cells, also
related to tooth development and repair of dentine.37,38 This pro-
tein appears at an early developmental stage of both the central
nervous system and muscles. Human nestin expression is present
during tooth development and disappears when development is
complete.38 Its expression has been reported in pathological condi-
tions, such as central and peripheral nervous system tumors.38 It
seems reasonable that some odontogenic tumors express nestin
because odontogenic ectomesenchymal tissue is derived from neu-
ral crest. Referring to OM, Fujita et al.38 reported four of nine cases
positive for nestin and a variable expression among various odon-
togenic tumors, probably related to the origin and the different
stages of differentiation of each group of tumor investigated. The
results of these authors imply that there are two possible histogen-
esis of OM affecting the jaw: the dental papilla cells of tooth germ
and mesenchymal cells such as ﬁbroblasts or myoﬁbroblasts other
than odontogenic ectomesenchyme.38
Conclusion
OMs are extensively described as case report studies. However,
larger studies investigating biomarkers related to OM development
and growth are necessary. Despite efforts to delineate molecular
aspects, the invasive behavior of these lesions has not been ex-
plained. These advances are imperative in order to establish new
approaches in the therapy of this ectomesenchymal odontogenic
tumor.
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